Are you importing or launching a regulated product in Colombia? Validate your position before INVIMA does.
Sanctions imposed by Colombia’s National Institute for Food and Drug Surveillance, INVIMA, often arise from recurring violations across regulated sectors. In the food and beverage industry, for example, non-compliance with Good Manufacturing Practices (GMP) and deficient hygiene and sanitary conditions in processing facilities are common. In the pharmaceutical sector, authorities frequently detect the commercialization of medicines or herbal products without the required sanitary registration, while in medical devices and cosmetics, recurring issues often relate to commercialization authorizations and labeling requirements.
Among the most commonly sanctioned conducts are the sale of products without the required sanitary registration, misleading or unauthorized health-related advertising, improper therapeutic claims, failure to comply with import-related sanitary requirements, and the commercialization of expired, adulterated, or contaminated products. These violations may lead to health and safety measures as well as administrative sanctions, including fines, product seizure, suspension of activities, or even closure of establishments, depending on the seriousness of the risk to public health.
For foreign companies, these issues are not merely regulatory. They can directly affect market-entry timing, distributor confidence, logistics planning, cost structure, and the overall credibility of the business in Colombia.
Main Types of Sanitary Violations in Colombia
The types of sanitary violations in Colombia, following a regulated product from market intent to compliant commercialization. Tap any step to jump to it.
Commercializing Products Without the Required Sanitary Registration
One of the most serious mistakes is to manufacture, import, distribute, or commercialize food, medicines, cosmetics, or medical devices without the relevant sanitary registration, permit, or sanitary notification granted by INVIMA.
In Colombia, many regulated products are subject to prior sanitary control. As a result, placing them on the market without the applicable authorization constitutes a sanitary violation.
- Law 9 of 1979
- Decree 677 of 1995 for medicines
- Decree 3075 of 1997 and Resolution 2674 of 2013 for food
- Decree 4725 of 2005 for medical devices
These situations may result in health and safety measures such as product seizure, suspension of activities, closure of establishments, and administrative fines.
Non-Compliance With Labeling Requirements
Another frequent issue is the failure to comply with mandatory sanitary labeling requirements.
Labels must include legally required information such as the identification of the manufacturer or importer, sanitary registration number where applicable, ingredients, expiration date, health warnings, and any other mandatory information under the relevant technical regulations.
For food products, these obligations are primarily governed by Resolution 810 of 2021, which sets the technical regulation on nutritional labeling and front-of-pack warning labeling.
Incorrect labeling may result in market withdrawal, product seizure, mandatory corrections, and administrative sanctions.
Unauthorized or Misleading Health-Related Advertising
In the case of medicines and other regulated products, health-related advertising is subject to specific restrictions.
The dissemination of promotional materials that have not been authorized, or that mislead consumers regarding the nature, use, benefits, or legal status of the product, may constitute a sanitary violation.
- Law 9 of 1979
- Decree 677 of 1995, particularly regarding the advertising of medicines
These violations may lead to advertising suspension orders, fines, and regulatory requirements issued by INVIMA.
Improper Use of Therapeutic or Medical Claims
A frequent mistake is attributing therapeutic, preventive, or curative properties to food products, dietary supplements, or cosmetics without authorization from the health authority.
Statements such as “cures disease,” “prevents cancer,” or “treats heart conditions” may constitute misleading advertising or a sanitary violation where the product is not legally classified as a medicine and lacks the supporting regulatory basis.
These practices may trigger corrective orders, suspension of advertising, product withdrawal, or broader regulatory scrutiny.
Failure to Comply With Sanitary Import Requirements
Foreign companies often underestimate the regulatory steps required to lawfully place products on the Colombian market.
Common mistakes include:
- failing to obtain prior sanitary registration where required;
- not providing manufacturer certificates;
- omitting technical product documentation;
- failing to meet sanitary import requirements.
- Decree 677 of 1995
- Decree 4725 of 2005
- Resolution 2674 of 2013
These shortcomings may lead to customs retention, seizure of goods, or prohibition of commercialization in Colombia.
Modifying Products Without Prior Notice or Approval
Products that already have a sanitary registration must remain consistent with the conditions under which they were authorized.
Changes involving formulation, manufacturer, registration holder, production process, or other relevant characteristics may need to be previously reported to or approved by INVIMA.
Making such changes without authorization may result in the suspension or cancellation of the sanitary registration.
- Decree 677 of 1995
- Decree 4725 of 2005
Non-Compliance With Good Manufacturing Practices (GMP)
Companies manufacturing regulated products must comply with technical standards known as Good Manufacturing Practices, intended to ensure quality, safety, and traceability.
These standards typically cover:
- hygienic and sanitary conditions of facilities;
- documentary control of processes;
- quality control systems;
- traceability of production.
- Decree 677 of 1995
- Resolution 2674 of 2013
Non-compliance may lead to temporary closure of facilities, suspension of activities, and economic sanctions.
Use of Unauthorized Ingredients or Substances
The use of prohibited or unauthorized ingredients is considered a serious sanitary violation.
Examples may include:
- unauthorized additives in food products;
- restricted ingredients in cosmetics;
- undeclared pharmacological substances in dietary supplements.
These situations often lead to immediate withdrawal of the product from the market and seizure of the goods.
Commercialization of Adulterated or Fraudulent Products
The sale of adulterated products, meaning products whose composition has been altered or which contain ingredients different from those declared, constitutes a sanitary violation under Colombian law.
- Law 9 of 1979
In addition to administrative sanctions, such conduct may, in certain cases, trigger criminal liability where public health is put at risk.
Failure to Renew Sanitary Registrations on Time
Sanitary registrations are valid only for a limited period and must be renewed within the legally established timeframes.
If a company fails to renew on time, the product may remain without a valid sanitary authorization, making its manufacture, importation, or commercialization unlawful.
- Decree 677 of 1995
- Decree 4725 of 2005
In these cases, INVIMA may impose both health and safety measures and administrative sanctions for irregular commercialization.
Ready to validate your regulatory position before entering the Colombian market?
Common Mistakes Made by Foreign Companies
Based on Colombian sanitary regulation and INVIMA’s enforcement approach, it is possible to identify a series of recurring mistakes made especially by importers and foreign companies seeking to introduce regulated products into Colombia.
These mistakes often include:
- assuming that approval in the country of origin is sufficient for Colombia;
- failing to obtain the applicable sanitary registration or notification before launch;
- using foreign labels without local regulatory adaptation;
- making aggressive claims that exceed what Colombian law allows;
- failing to structure the registration holder properly;
- importing products without the required technical or supporting documentation;
- modifying products after authorization without evaluating the regulatory implications;
- underestimating the time needed for market entry from a regulatory standpoint.
From a business perspective, the consequences often appear as delayed market entry, reduced trust from the local distributor, logistical friction, correction costs, and an early impression of poor regulatory preparation.
Before importing, launching, or scaling a regulated product in Colombia, it is advisable to validate the regulatory route, technical documentation, labeling, and commercialization structure. At Nieto Lawyers, we assist foreign companies in identifying these issues before they become costly barriers to entry.
FAQ
The most common sanitary violations usually involve commercialization without the required sanitary registration, incorrect or misleading labeling, unauthorized advertising, improper therapeutic claims, importation without sufficient regulatory support, and failures related to hygiene, traceability, or Good Manufacturing Practices. In practice, these issues may trigger health and safety measures, administrative proceedings, and significant commercial disruption.
Not necessarily. Approval in the country of origin does not automatically authorize commercialization in Colombia. Foreign companies must verify the applicable Colombian regulatory pathway for the product, including whether a sanitary registration, permit, or mandatory sanitary notification is required.
No. The applicable route depends on the category of the product. Some products require a full sanitary registration, while others may be subject to a permit, notification, or a different regulatory mechanism. The legal route must be assessed case by case before importation or launch.
If a product is commercialized without the applicable sanitary authorization, INVIMA may adopt health and safety measures such as seizure, immobilization, suspension of commercialization, or closure of the establishment, without prejudice to the corresponding sanctioning procedure.
Approximate INVIMA Processing Times
The following timeframes are indicative only and may vary depending on the product category, the quality of the documentation submitted, technical review complexity, and administrative workload.
Timing Reality Check: INVIMA procedures should not be planned with fixed timelines. The table below reflects predictability ranges, not guaranteed timeframes.
Do not assume all products follow the same timing. Verify first whether the product falls within the routes currently handled through InvimÁgil or under a different procedural path.
Incorrect risk classification, incomplete company registration, failure to complete the digital route, and dossier errors.
Since July 2025, INVIMA has stated that certain registrations, permits, and notifications for food and non-alcoholic beverages may be self-managed through InvimÁgil in as little as 24 hours, but this should not be generalized to all products or situations. (Invima)
Build conservative launch timelines and assume technical review may take longer if the dossier is complex or requires clarification.
Pharmacological evaluation complexity, technical deficiencies, requests for additional information, and product-specific review burdens.
INVIMA provides medicines-specific formats and technical requirements, which shows that review depends heavily on the type of medicine and the quality of the supporting file, not on a single universal clock. (Invima)
Plan by device classification and technical complexity, not by a single standard estimate.
Incomplete technical file, risk-classification issues, missing supporting documents, and modification/
INVIMA’s own forms and guidance for devices focus on classification, documentation and type of procedure, which is a sign that timing depends on the specific case. (Invima)
Confirm the exact legal route first: NSO, renewal, amendment, or other associated procedure.
Errors in formulas, supporting documentation, holder data, or failure to comply with the current Andean framework.
For cosmetics, the legal framework has to be read today in light of Andean Decision 833 of 2018, not just older references. Timing should therefore be described carefully and linked to the actual NSO route in force. (Normograma INVIMA)
Never leave these for the last minute. Build internal alerts and review whether the intended change requires prior filing or approval.
Late filings, poor change control, incomplete comparison data, and misunderstanding of the applicable amendment route.
In practice, amendments and renewals are not just “administrative updates”; in regulated sectors they can materially affect continuity of commercialization if poorly managed. INVIMA’s guidance for medicine modifications is a good example of that. (Invima)
Illustrative Enforcement Scenarios
Colombian health authorities have imposed multiple sanctions on companies across different sectors for non-compliance with sanitary regulations. Recurrent scenarios include:
- food companies sanctioned for manufacturing or commercializing products without the required sanitary registration or without meeting mandatory hygienic and sanitary conditions;
- dairy producers sanctioned for failing to comply with food safety technical regulations, leading to fines and product seizure;
- cosmetic and household product companies sanctioned for commercializing products without the required mandatory sanitary notification or for failing to comply with labeling requirements.
These administrative actions show that failures such as lack of sanitary registration, irregular labeling, unauthorized advertising, or commercialization of adulterated products may lead to significant fines, product seizure, suspension of activities, and even closure of establishments under Colombia’s National Health Code and the applicable sector-specific regulations.
Final Thoughts
For foreign companies, Colombia offers significant commercial opportunities, but entering a regulated market without a clear sanitary strategy can generate avoidable delays, costs, and exposure.
In many cases, the issue is not the product itself, but the way it is classified, documented, labeled, promoted, imported, or modified after authorization. This is why regulatory compliance should be addressed not merely as a filing exercise, but as part of the broader market-entry strategy.
At Nieto Lawyers, we advise foreign manufacturers, importers, distributors, and investors on how to approach Colombian sanitary regulation with greater legal certainty, stronger documentation, and a more reliable route to commercialization.
If your company is preparing to enter the Colombian market with food products, medicines, cosmetics, medical devices, supplements, or other regulated goods, an early regulatory review can make the difference between an orderly launch and an avoidable compliance problem.
